SV2A missense mutation facilitates the kindling epileptogenesis

被引：0
|
作者：
Ohno, Yukihiro [1 ]
Mashimo, Tomoji [2 ]
Okumura, Takahiro [1 ]
Ishihara, Shizuka [1 ]
Terada, Ryo [1 ]
Shimizu, Saki [1 ]
Tokudome, Kentaro [1 ]
Chie, Tomita [1 ]
Kitaya, Ryosuke [1 ]
Tanaka, Tomoya [1 ]
Kunisawa, Naofumi [1 ]
Sasa, Masashi [3 ]
Serikawa, Tadao [2 ]
机构：
[1] Osaka Univ Pharm Sci, Pharmacol Lab, Takatsuki, Osaka 5691094, Japan
[2] Kyoto Univ, Sch Med, Inst Lab Anim, Sakyo Ku, Kyoto 6068501, Japan
[3] Nagisa Clin, Hirakata, Osaka 5731183, Japan
来源：
JOURNAL OF PHARMACOLOGICAL SCIENCES | 2013年 / 121卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：87P / 87P
页数：1
相关论文
共 50 条
  • [31] An Epilepsy-Associated SV2A Mutation Disrupts Synaptotagmin-1 Expression and Activity-Dependent Trafficking
    Harper, Callista B.
    Small, Christopher
    Davenport, Elizabeth C.
    Low, Darryl W.
    Smillie, Karen J.
    Martinez-Marmol, Ramon
    Meunier, Frederic A.
    Cousin, Michael A.
    JOURNAL OF NEUROSCIENCE, 2020, 40 (23): : 4586 - 4595
  • [32] Visualization of SV2A conformations in situ by the use of Protein Tomography
    Lynch, Berkley A.
    Matagne, Alain
    Braennstrom, Annika
    von Euler, Anne
    Jansson, Magnus
    Hauzenberger, Elenor
    Soederhaell, J. Arvid
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 375 (04) : 491 - 495
  • [33] Targeting hippocampal amyloidogenesis with SV2A protein modulator levetiracetam
    Kasatkina, Ludmila A.
    Gumenyuk, Vitaliy P.
    Lisakovska, Olha O.
    Trikash, Irene O.
    BIOCHEMICAL PHARMACOLOGY, 2022, 197
  • [34] Evidence for a Differential Interaction of Brivaracetam and Levetiracetam with the SV2A Protein
    Wood, Martyn
    Galard, Michel
    NEUROLOGY, 2016, 86
  • [35] SV2A synaptic density PET may be affected by neuronal activity
    Toyonaga, T.
    Cai, Z.
    Holden, D.
    Fowles, K.
    Finnema, S. J.
    Huang, Y.
    Carson, R. E.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2019, 39 : 165 - 165
  • [36] Imaging the effect of ketamine on synaptic density (SV2A) in the living brain
    Sophie E. Holmes
    Sjoerd J. Finnema
    Mika Naganawa
    Nicole DellaGioia
    Daniel Holden
    Krista Fowles
    Margaret Davis
    Jim Ropchan
    Paul Emory
    Yunpeng Ye
    Nabeel Nabulsi
    David Matuskey
    Gustavo A. Angarita
    Robert H. Pietrzak
    Ronald S. Duman
    Gerard Sanacora
    John H. Krystal
    Richard E. Carson
    Irina Esterlis
    Molecular Psychiatry, 2022, 27 : 2273 - 2281
  • [37] 2 TYPES OF CHRONIC EPILEPTOGENESIS IN RABBITS DURING KINDLING STIMULATION OF THE HIPPOCAMPUS
    GRIGOREV, YG
    TIMOFEEVA, OA
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 1984, 97 (01) : 15 - 18
  • [38] Reductions in synaptic marker SV2A in early-course Schizophrenia
    Yoon, Jong H.
    Zhang, Zhener
    Mormino, Elizabeth
    Davidzon, Guido
    Minzenberg, Michael J.
    Ballon, Jacob
    Kalinowski, Agnieszka
    Hardy, Kate
    Naganawa, Mika
    Carson, Richard E.
    Khalighi, Mehdi
    Park, Jun Hyung
    Levinson, Douglas F.
    Chin, Frederick T.
    JOURNAL OF PSYCHIATRIC RESEARCH, 2023, 161 : 213 - 217
  • [39] Seletracetam, a small-molecule SV2A modulator for the treatment of epilepsy
    Pollard, John R.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (01) : 101 - 107
  • [40] Calcium inhibits the interaction between SV2A and multiple synaptotagmin isoforms
    Schivell, AE
    Gallagher, D
    Bajjalieh, SM
    MOLECULAR BIOLOGY OF THE CELL, 1999, 10 : 216A - 216A
12345